Acorah Software Products - Accounts Production 19.3.600 false true 31 August 2024 1 September 2023 false 1 September 2024 31 August 2025 31 August 2025 12822135 Mr D R Kennett Mr A P Kennett iso4217:GBP iso4217:EUR iso4217:USD xbrli:shares xbrli:pure xbrli:pure 12822135 2024-08-31 12822135 2025-08-31 12822135 2024-09-01 2025-08-31 12822135 frs-core:Non-currentFinancialInstruments 2025-08-31 12822135 frs-core:ComputerEquipment 2025-08-31 12822135 frs-core:ComputerEquipment 2024-09-01 2025-08-31 12822135 frs-core:ComputerEquipment 2024-08-31 12822135 frs-core:FurnitureFittings 2025-08-31 12822135 frs-core:FurnitureFittings 2024-09-01 2025-08-31 12822135 frs-core:FurnitureFittings 2024-08-31 12822135 frs-core:ShareCapital 2025-08-31 12822135 frs-core:RetainedEarningsAccumulatedLosses 2025-08-31 12822135 frs-bus:PrivateLimitedCompanyLtd 2024-09-01 2025-08-31 12822135 frs-bus:FilletedAccounts 2024-09-01 2025-08-31 12822135 frs-bus:SmallEntities 2024-09-01 2025-08-31 12822135 frs-bus:AuditExempt-NoAccountantsReport 2024-09-01 2025-08-31 12822135 frs-bus:SmallCompaniesRegimeForAccounts 2024-09-01 2025-08-31 12822135 frs-bus:Director1 2024-09-01 2025-08-31 12822135 frs-bus:Director2 2024-09-01 2025-08-31 12822135 frs-countries:EnglandWales 2024-09-01 2025-08-31 12822135 2023-08-31 12822135 2024-08-31 12822135 2023-09-01 2024-08-31 12822135 frs-core:CurrentFinancialInstruments 2024-08-31 12822135 frs-core:Non-currentFinancialInstruments 2024-08-31 12822135 frs-core:ShareCapital 2024-08-31 12822135 frs-core:RetainedEarningsAccumulatedLosses 2024-08-31
Registered number: 12822135
WebRx Pharma Ltd
Unaudited Financial Statements
For The Year Ended 31 August 2025
Contents
Page
Balance Sheet 1—2
Notes to the Financial Statements 3—4
Page 1
Balance Sheet
Registered number: 12822135
2025 2024
Notes £ £ £ £
FIXED ASSETS
Tangible Assets 4 1,140 2,330
1,140 2,330
CURRENT ASSETS
Stocks 5 - 75,000
Debtors 6 1,450 101,446
Cash at bank and in hand 70,098 164,815
71,548 341,261
Creditors: Amounts Falling Due Within One Year 7 (20,328 ) (184,072 )
NET CURRENT ASSETS (LIABILITIES) 51,220 157,189
TOTAL ASSETS LESS CURRENT LIABILITIES 52,360 159,519
Creditors: Amounts Falling Due After More Than One Year 8 (5,000 ) (5,000 )
NET ASSETS 47,360 154,519
CAPITAL AND RESERVES
Called up share capital 75 100
Profit and Loss Account 47,285 154,419
SHAREHOLDERS' FUNDS 47,360 154,519
Page 1
Page 2
For the year ending 31 August 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.
The company has taken advantage of section 444(1) of the Companies Act 2006 and opted not to deliver to the registrar a copy of the company's Profit and Loss Account.
On behalf of the board
Mr D R Kennett
Director
28/08/2026
The notes on pages 3 to 4 form part of these financial statements.
Page 2
Page 3
Notes to the Financial Statements
1. General Information
WebRx Pharma Ltd is a private company, limited by shares, incorporated in England & Wales, registered number 12822135 . The registered office is 71-75 Shelton Street, London, Greater London, WC2H 9JQ.
2. Accounting Policies
2.1. Basis of Preparation of Financial Statements
The financial statements have been prepared under the historical cost convention and in accordance with Financial Reporting Standard 102 section 1A Small Entities "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006.
2.2. Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.
2.3. Tangible Fixed Assets and Depreciation
Tangible fixed assets are measured at cost less accumulated depreciation and any accumulated impairment losses. Depreciation is provided at rates calculated to write off the cost of the fixed assets, less their estimated residual value, over their expected useful lives on the following bases:
Fixtures & Fittings 25% on cost
Computer Equipment 25% on cost
2.4. Stocks and Work in Progress
Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.
2.5. Financial Instruments
The Company only enters into basic financial instrument transactions that result in the recognition of financial assets and liabilities like trade and other debtor and creditors, loans from banks and other third parties, loans to related parties and investments in ordinary shares.
Debt instruments (other than those wholly repayable or receivable within one year), including loans and other accounts receivable and payable, are initially measured at present value of future cash flows and subsequently amortised cost using the effective interest method.
Debt instruments that are payable or receivable within one year, typically trade debtors and creditors, are measured, initially and subsequently, at the un-discounted amount of the cash or other consideration to be paid or received . However, if the arrangements of a short-term instrument constitute a financing transaction, like the payment of a trade debt deferred beyond normal business terms or in case of an out-right short-term loan that is not at market rate, the financial asset or liability market rate of interest for similar debt instrument and
subsequently at amortised cost, unless it qualifies as a loan from a Director in the case of a small Company, or public benefit entity of concessionary loan.
Financial assets that are measured at cost and amortised cost are assessed at the end of each reporting period for objective evidence and impairment. If objective evidence of impairment is found, an impairment loss if recognised in the Statement of Comprehensive Income.
2.6. Creditors
Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.
2.7. Debtors
Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment
3. Average Number of Employees
Average number of employees, including directors, during the year was: 1 (2024: 1)
1 1
Page 3
Page 4
4. Tangible Assets
Fixtures & Fittings Computer Equipment Total
£ £ £
Cost
As at 1 September 2024 2,855 3,503 6,358
As at 31 August 2025 2,855 3,503 6,358
Depreciation
As at 1 September 2024 1,605 2,423 4,028
Provided during the period 714 476 1,190
As at 31 August 2025 2,319 2,899 5,218
Net Book Value
As at 31 August 2025 536 604 1,140
As at 1 September 2024 1,250 1,080 2,330
5. Stocks
2025 2024
£ £
Stock - 75,000
6. Debtors
2025 2024
£ £
Due within one year
Trade debtors - 1,394
Other debtors 1,450 100,052
1,450 101,446
7. Creditors: Amounts Falling Due Within One Year
2025 2024
£ £
Trade creditors - 24,172
Other loans - 20,000
Other creditors 20,328 139,900
20,328 184,072
8. Creditors: Amounts Falling Due After More Than One Year
2025 2024
£ £
Other loans 5,000 5,000
Page 4